<unk>  is used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the IDH2 gene, determined by an FDA-approved IDH2 companion diagnostic test.
Enasidenib
Ivosidenib
Dabrafenib
Brigatinib
Tucatinib
Selpercatinib
Fostamatinib
Lorlatinib